# Reverse Transcription PCR Inhibition ## Quick Answer - RT-PCR inhibition occurs when contaminants in RNA preparations block reverse transcriptase activity or downstream polymerase function, producing false negatives or skewed quantification. - The practical first step is to run inhibitor controls, including spike-in RNA and no-template controls, before interpreting any negative or quantitative result. - No single purification method removes all inhibitors, so you must match extraction chemistry to your sample type and verify removal with quality metrics. ## Understanding Reverse Transcription PCR Inhibition Reverse transcription PCR (RT-PCR) combines two enzymatic steps: reverse transcriptase converts RNA into complementary DNA (cDNA), and then DNA polymerase amplifies that cDNA. Each enzyme has distinct sensitivity to contaminants that may be present in biological samples. Inhibitors can act at either step, and some compounds affect both enzymes. The practical consequence is that a sample can appear to have no target RNA when the RNA is actually present but the enzymes are blocked. Inhibitors enter the reaction through the sample matrix, extraction reagents, or laboratory consumables. Blood, soil, plant tissue, feces, and formalin-fixed tissues each carry different inhibitor profiles. The same extraction kit may perform well for one sample type and poorly for another. Researchers must therefore treat inhibition as a sample-specific problem instead of a universal one. The reverse transcription step is often the most vulnerable point because reverse transcriptase enzymes are generally more sensitive to salts and organic solvents than thermostable DNA polymerases. This means that a purification method that works for PCR may still leave enough contaminant to suppress cDNA synthesis. The result is a failure that appears only after amplification, when the cDNA is already absent or reduced. Inhibition is not always complete. Partial inhibition produces delayed amplification curves, reduced endpoint fluorescence, or inconsistent replicates. These subtle effects are more dangerous than complete failure because they can be mistaken for genuine biological variation. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) emphasize that reporting must include sufficient detail about sample processing and quality control so that readers can assess whether inhibition may have influenced the results. ## At a Glance | Inhibitor Class | Common Sources | Primary Target | Detection Method | Mitigation Strategy | | --- | --- | --- | --- | --- | | Salts | RNA extraction elution buffers, high-salt precipitation | Reverse transcriptase and DNA polymerase | Spike-in control, dilution series | Dilute cDNA, use ethanol precipitation, desalting columns | | Organic solvents | Phenol, ethanol, guanidinium salts | Reverse transcriptase | Absorbance ratio, spike-in control | Increase ethanol wash, use silica column purification | | Polysaccharides | Plant tissues, some bacterial cultures | DNA polymerase | Serial dilution, spike-in control | Use CTAB extraction, add BSA to reaction | | Heme compounds | Blood, tissue | DNA polymerase | Spike-in control, dilution | Use specialized blood extraction kits, increase purification stringency | | Humic acids | Soil, sediment, water | Reverse transcriptase and DNA polymerase | Dilution series, spike-in control | Use soil-specific kits, add BSA, dilute template | This table summarizes the most common inhibitor classes and the practical steps you can take to detect and reduce their effects. The detection methods listed are not exhaustive, and you should combine them with the controls described in the MIQE guidelines. ## Core Principles of RT-PCR Inhibition ### How Inhibitors Interfere with Reverse Transcriptase Reverse transcriptase is a RNA-dependent DNA polymerase that requires specific conditions for optimal activity. It is a metal-dependent enzyme that needs magnesium ions for catalysis. Many inhibitors act by chelating magnesium, making it unavailable to the enzyme. Other inhibitors bind directly to the enzyme or to the RNA template, preventing the enzyme from reading the sequence. The reverse transcription step is typically performed at lower temperatures than PCR, often around 42 to 50 degrees Celsius. This lower temperature means that inhibitors that are not stable at high temperatures may still be active during cDNA synthesis. For example, some organic solvents that would evaporate or degrade during the high-temperature denaturation step of PCR can remain in the reaction during reverse transcription. The result is that a sample can pass a DNA quality check but still fail in RT-PCR. The DNA polymerase may be able to amplify a DNA template even with some contamination, but the reverse transcriptase cannot produce the cDNA in the first place. This is why RT-PCR inhibition is often more severe than PCR inhibition for the same sample. ### Inhibitors That Target the PCR Step Once cDNA is synthesized, the PCR step can still be inhibited by contaminants that carry over from the RT reaction. These inhibitors may be the same ones that affected the reverse transcriptase, or they may be new ones introduced during the cDNA synthesis reaction. For example, the reverse transcriptase reaction buffer contains components that can inhibit PCR if they are carried over in high concentration. The PCR step is also sensitive to inhibitors that affect the DNA polymerase. These include compounds that bind to the DNA template, preventing the polymerase from reading the sequence, and compounds that interfere with the polymerase itself. Some inhibitors can also affect the fluorescent probes used in quantitative PCR, producing a signal that does not reflect the actual amount of product. ### The Role of RNA Quality in Inhibition RNA quality is a separate issue from inhibition, but the two are often confused. RNA that is degraded will produce weak or absent amplification even without inhibitors. RNA that is contaminated with genomic DNA will produce false positive results if the primers are not designed to distinguish cDNA from genomic DNA. The [Addgene protocols](https://www.addgene.org/protocols) provide general guidance for RNA extraction and quality assessment. These protocols are educational and not universally validated, but they describe the standard steps of RNA purification, including the use of DNase treatment to remove genomic DNA. The quality of the RNA should be assessed before RT-PCR, and the results should be interpreted with the understanding that RNA quality and inhibition are separate but related problems. ## Practical Workflow for Detecting and Managing RT-PCR Inhibition ### Step 1: Assess RNA Quality and Quantity Before performing RT-PCR, you should measure the RNA concentration and purity. The most common method is spectrophotometry, which measures absorbance at 260 nanometers for nucleic acids and 280 nanometers for proteins. The ratio of these absorbances is often used as a purity indicator. However, this ratio is not a reliable indicator of inhibition because many inhibitors do not absorb at these wavelengths. A more reliable method is to use a fluorometric assay that specifically detects RNA. These assays are less affected by contaminants than spectrophotometry. The [NIST laboratory programs](https://www.nist.gov/laboratories) emphasize the importance of measurement science and calibration in laboratory work. You should calibrate your fluorometer and use standards to ensure that your measurements are accurate. ### 2: Run a Spike-In Control A spike-in control is a known amount of RNA that is added to the sample before extraction or before RT-PCR. If the spike-in RNA is not amplified, the sample contains an inhibitor. The spike-in should be a different sequence from the target so that it can be detected separately. The spike-in control is the most direct way to detect inhibition. It is not a perfect control because the spike-in RNA may behave differently from the target RNA, but it is a practical and widely used method. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the spike-in control be reported in the methods section so that readers can assess the validity of the results. ### 3. Dilute the Sample Dilution is a simple and effective way to reduce the concentration of inhibitors. If the target RNA is present in sufficient quantity, diluting the sample can reduce the inhibitor concentration below the threshold that affects the enzymes. The dilution factor should be determined empirically for each sample type. Dilution has a limitation: it also dilutes the target RNA. If the target RNA is present at a low concentration, dilution may make it undetectable. The dilution should be tested in a series, such as 1:10, 1:100, and 1:1000, to find the dilution that reduces inhibition without losing the target signal. ### 4. Use a Purification Method If dilution does not solve the problem, the sample should be purified further. The purification method depends on the type of inhibitor. For example, phenol contamination can be removed by an additional ethanol precipitation. Salt contamination can be removed by a column purification step. The [Addgene protocols](https://www.addgene.org/protocols) describe several purification methods, including column-based and precipitation-based methods. These protocols are educational and should be adapted to the specific sample type. The purification method should be validated by running a spike-in control after purification to confirm that the inhibitor has been removed. ### 5. Add a Carrier or Enhancer Some inhibitors can be neutralized by adding a carrier protein or a chemical enhancer to the reaction. For example, bovine serum albumin (BSA) can bind to some inhibitors and prevent them from interfering with the enzyme. The concentration of BSA should be optimized for the specific reaction. The use of BSA is not a substitute for purification. It is a supplementary measure that can improve the reaction in the presence of low-level inhibitors. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the use of BSA or other additives be reported in the methods section. ## Common Failure Patterns and Their Causes ### Pattern 1: Complete Absence of Amplification A complete absence of amplification in a sample that is known to contain the target RNA is a strong indication of inhibition. The cause may be a high concentration of an inhibitor that blocks the reverse transcriptase or the DNA polymerase. The first step is to run a spike-in control to confirm that the sample is inhibitory. If the spike-in control also fails, the sample is inhibitory. The next step is to dilute the sample and test again. If the dilution restores the signal, the inhibitor is present at a concentration that can be diluted out. If the dilution does not restore the signal, the inhibitor is present at a very high concentration or the RNA is degraded. ### Failure Pattern 2: Delayed Amplification Delayed amplification is a common pattern in which the amplification curve is shifted to a higher Ct value than expected. This pattern is caused by a low concentration of an inhibitor that slows the reaction but does not stop it. The delayed amplification can be mistaken for a low concentration of the target RNA. The spike-in control is the best way to distinguish delayed amplification from a low target concentration. If the spike-in is also delayed, the sample is inhibitory. If the spike-in is not delayed, the target RNA is present at a low concentration. ### Failure Pattern 3: Inconsistent Replicates Inconsistent replicates are a sign of variable inhibition. The inhibitor may be distributed unevenly in the sample, or the extraction may have produced inconsistent purification. The replicates should be repeated with a more thorough mixing of the sample and a more consistent extraction protocol. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the number of replicates and the variation between replicates be reported. This allows the reader to assess the reliability of the results. ### Failure Pattern 4: False Negative A false negative is a sample that is reported as negative but actually contains the target RNA. This is the most dangerous failure pattern because it can lead to a wrong conclusion. The false negative is caused by an inhibitor that is not detected by the quality control measures. The best way to prevent false negatives is to use a spike-in control in every sample. The spike-in control is the only way to confirm that the reaction is working in the presence of the sample. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the spike-in control be included in the experimental design. ## Records and Measurements for RT-PCR Inhibition ### What to Record The following records should be kept for each RT-PCR run: - The sample type and source - The extraction method and kit - The RNA concentration and purity - The spike-in control result - The dilution factor used - The Ct values for the target and the spike-in - The reaction conditions, including the enzyme and buffer These records allow you to compare the results across runs and to identify patterns of inhibition. The [NIST laboratory programs](https://www.nist.gov/laboratories) emphasize the importance of measurement traceability and quality control. The records should be kept in a laboratory notebook or an electronic system that is accessible to all members of the laboratory. ### How to Use the Records The records should be reviewed regularly to identify trends. For example, if a particular sample type consistently shows inhibition, the extraction method should be changed. If a particular batch of reagent is associated with inhibition, the reagent should be replaced. The records should also be used to validate the performance of the RT-PCR assay. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the performance of the assay be assessed by the efficiency, the limit of detection, and the reproducibility. These parameters should be measured and recorded for each assay. ## Common Failure Patterns and Their Causes ### Failure Pattern 1: No Amplification No amplification is the most obvious sign of inhibition. The sample may be negative for the target RNA, or the sample may be inhibited. The spike-in control is the only way to distinguish these two possibilities. If the spike-in is also negative, the sample is inhibited. If the spike-in is positive, the sample is negative for the target. ### Failure Pattern 2: The Amplification is Delayed Delayed amplification is a more subtle sign of inhibition. The sample may be positive, but the Ct value is higher than expected. The spike-in control is the best way to determine if the delay is due to inhibition or to a low target concentration. ### Failure Pattern 3: The Amplification is Inconsistent Inconsistent amplification is a sign of variable inhibition. The sample may be positive in one replicate and negative in another. The spike-in control can help to determine if the inconsistency is due to inhibition or to the sample. ### Failure Pattern 4: The Amplification is Non-Specific Non-specific amplification is a sign of contamination or of a primer that is not specific. The spike-in control can help to determine if the non-specific amplification is due to the sample or to the reaction. ## Biosafety and Regulatory Context ### Biosafety Principles RT-PCR involves the use of biological samples that may contain infectious agents. The [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) provides the principles of biosafety, including risk assessment, containment, and institutional oversight. The risk assessment should be performed before the work begins, and the appropriate containment should be used. The [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules) provide the official oversight for research involving recombinant or synthetic nucleic acids. RT-PCR is often used in this research, and the guidelines should be followed. ### Regulatory Context The regulatory context for RT-PCR depends on the application. For clinical diagnostics, the assay must be validated and approved by the relevant regulatory body. For research, the assay must be performed in accordance with the institutional guidelines. The [NIST laboratory programs](https://www.nist.gov/laboratories) provide the measurement science and standards that are used to validate the assay. ## Limitations and Professional Escalation ### Limitations of the Methods The methods described in this article are not universal. The spike-in control is a valid method, but it is not a perfect control. The spike-in RNA may not behave in the same way as the target RNA. The dilution is a valid method, but it may not be effective for all inhibitors. The purification is a valid method, but it may not remove all inhibitors. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the limitations of the assay be reported. The limitations should be considered when interpreting the results. ### When to Escalate The escalation should be considered when the inhibition cannot be resolved by the methods described in this article. The escalation may involve the following: - The use of a different extraction method - The use of a different purification method - The use of a different RT-PCR kit - The use of a different detection method The escalation should be performed in consultation with a laboratory supervisor or a specialist. The [NIST laboratory programs](https://www.nist.gov/laboratories) provide the standards and the measurement science that can be used to the escalation. ## A Decision Framework for Selecting Inhibitor Controls and Internal Amplification Strategies The existing workflow describes spike-in controls as a general tool, but it does not provide a structured method for choosing which control strategy fits a given experimental context. Researchers often default to a single control type without considering whether that control can actually detect the inhibitor class present in their samples. This section provides a practical decision framework that matches control strategies to sample types, experimental goals, and the specific inhibitors you expect to encounter. ### The Control Hierarchy: From Simple to Diagnostic Inhibitor controls exist on a spectrum from simple detection to diagnostic identification. The simplest control tells you that something is wrong. A more sophisticated control tells you what is wrong and where the problem occurred. The framework below organizes these controls by their diagnostic power and their practical requirements. #### Level 1: The No-Template Control The no-template control (NTC) contains all reaction components except the RNA template. This control detects contamination of the reaction master mix, not inhibition of the sample. An NTC that produces amplification indicates that the reagents or the environment are contaminated with the target sequence or with amplicons from previous reactions. The NTC is a mandatory control for every RT-PCR run, but it does not provide any information about whether your sample inhibits the reaction. A clean NTC only tells you that the reaction components are functional in the absence of a sample. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) require that the NTC be reported for every qPCR experiment, and the same standard applies to RT-PCR. #### Level 2: The External Spike-In Control The external spike-in control is a known quantity of a synthetic or heterologous RNA that is added to the sample before extraction or before the RT step. This control travels through the same purification and reverse transcription processes as the target RNA. If the spike-in fails to amplify, the sample contains an inhibitor that affects the RT step or the PCR step. The external spike-in is the most direct method for detecting inhibition, but it has a critical limitation. The spike-in RNA is a different sequence from the target, and it may have different secondary structure, length, or GC content. These differences can affect how the spike-in responds to inhibitors. A spike-in that is shorter or more stable than the target may be less sensitive to inhibition, producing a false negative result for the control. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the spike-in be reported with its sequence, concentration, and the step at which it was added. This information allows the reader to assess whether the spike-in is an appropriate control for the target. #### Level 3: The Internal Reference Gene Control The internal reference gene control uses an endogenous RNA that is present in the sample. This control is amplified in the same reaction or in a parallel reaction. The reference gene is typically a housekeeping gene that is expressed at a relatively constant level across the samples being compared. The internal reference gene control has an advantage over the external spike-in because it is present in the sample from the beginning. It is subject to the same extraction, purification, and reverse transcription processes as the target RNA. However, the reference gene is not a perfect control for inhibition because it may be present at a different concentration than the target. If the target is present at a very low concentration and the reference gene is present at a high concentration, the reference gene may amplify even when the target is inhibited. The reference gene control is most useful when the target and the reference gene are present at similar concentrations. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the reference gene be validated for the specific sample type and experimental condition before it is used as a control. #### Level 4: The Multiplexed Internal Control The multiplexed internal control is a synthetic RNA that is added to the reaction and amplified in the same tube as the target. The control is designed with a different probe or a different melting temperature so that it can be distinguished from the target. This control is the most informative because it is amplified in the same reaction as the target, so it is subject to the same conditions. The multiplexed control is the most sensitive to inhibition because it is present in the same reaction as the target. If the control is inhibited, the target is also inhibited. The multiplexed control is also the most difficult to design because the control and the target must not interfere with each other. The primers and probes must be designed to avoid cross-reactivity, and the amplification of the control must not compete with the amplification of the target. The [Addgene protocols](https://www.addgene.org/protocols) provide general guidance for multiplex PCR design, including the need to test primer combinations for cross-reactivity. The multiplexed control is the most informative control for inhibition, but it requires the most development time. ### Matching the Control to the Sample Type The choice of control depends on the sample type and the expected inhibitors. The table below provides a practical starting point for selecting the control level. | Sample Type | Expected Inhibitor | Recommended Control Level | Rationale | | --- | --- | --- | --- | | Purified RNA from cell culture | Low inhibitor load | Level 2 external spike | The extraction is clean, and the spike-in is sufficient to detect residual inhibitors | | Blood or serum | Heme compounds, salts | Level 3 internal reference | The reference gene is present in the sample and is subject to the same extraction as the target | | Plant tissue | Polysaccharides, phenolics | Level 4 multiplexed | The inhibitor load is high, and the multiplexed control is the most sensitive | | Soil or sediment | Humic acids | Level 4 multiplexed | The inhibitor load is very high, and the multiplexed control is the most sensitive | | Formalin-fixed tissue | Cross-linking agents | Level 3 internal reference | The extraction is complex, and the reference gene is the most reliable control | This table is a starting point, not a fixed rule. The control level should be adjusted based on the results of the initial runs. If the external spike-in control fails, the sample should be tested with a more sensitive control. ### The Dilution Series as a Diagnostic Tool The dilution series is beyond a mitigation strategy. It is also a diagnostic tool that can distinguish between inhibition and a low target concentration. The dilution series is performed by preparing a serial dilution of the sample, such as 1:10, 1:100, and 1:1000, and running each dilution in the RT-PCR. The interpretation of the dilution series depends on the pattern of the Ct values. If the Ct values increase by approximately 3.3 cycles for each 10-fold dilution, the reaction is working correctly and the target is present at a concentration that is proportional to the dilution. If the Ct values do not increase as expected, the sample is inhibited. The dilution series is also useful for determining the optimal dilution for the sample. The optimal dilution is the highest dilution that still produces a detectable signal. This dilution reduces the inhibitor concentration while preserving the target signal. The [NIST laboratory programs](https://www.nist.gov/laboratories) emphasize the importance of calibration and measurement traceability. The dilution series should be performed with a calibrated pipette and the results should be recorded in the laboratory notebook. ### The Inhibition Index: A Quantitative Measure The inhibition index is a quantitative measure of the degree of inhibition in a sample. It is calculated by comparing the Ct value of the spike-in control in the sample to the Ct value of the spike-in control in a reference sample that is known to be free of inhibitors. The inhibition index is calculated as follows: Inhibition index = Ct(sample spike-in) - Ct(reference spike-in) A value of zero indicates that the sample is not inhibited. A positive value indicates that the sample is inhibited, and the magnitude of the value indicates the degree of inhibition. A value of 3.3 indicates that the sample is inhibited by a factor of 10, and a value of 6.6 indicates that the sample is inhibited by a factor of 100. The inhibition index is a useful tool for comparing the inhibition across samples and across experiments. It is also useful for tracking the effectiveness of the purification methods. If the inhibition index decreases after purification, the purification is effective. The inhibition index should be recorded for each sample and each purification step. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the inhibition index be reported in the methods section so that the reader can assess the validity of the results. ### The Purification Decision Tree The purification decision tree is a structured method for selecting the purification method based on the inhibitor type. The tree is based on the inhibitor classes described in the At a Glance table. The first step is to identify the inhibitor class. This is done by running the spike-in control and the dilution series. If the spike-in fails and the dilution restores the signal, the inhibitor is present at a concentration that can be diluted out. If the dilution does not restore the signal, the inhibitor is present at a high concentration or the RNA is degraded. The next step is to select the purification method based on the inhibitor class. The purification methods are described in the At a Glance table. The purification method should be validated by running the spike-in control after purification. The purification decision matrix is a practical tool for the laboratory. It is not a substitute for the judgment of the researcher. The researcher should consider the sample type, the inhibitor class, and the available resources when selecting the purification method. ### The Role of the Reference Gene in the Decision Framework The reference gene is a critical component of the decision framework. The reference gene is an endogenous RNA that is present in the sample. It is used to normalize the target gene expression and to detect the inhibition. The reference gene is not a perfect control for inhibition. It is present at a different concentration than the target, and it may be affected by the inhibitors in a different way. However, the reference gene is a useful control because it is present in the sample from the beginning and is subject to the same extraction and reverse transcription processes as the target. The reference gene should be validated for the specific sample type and experimental condition. The validation should include the following: - The reference gene should be expressed at a stable level across the samples. - The reference gene should not be affected by the experimental condition. - The reference gene should be amplified with the same efficiency as the target. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) recommend that the reference gene be validated and reported in the methods section. ### The Decision Framework in Practice The decision framework is a practical tool for the laboratory. It is not a rigid protocol. The researcher should use the framework to guide the decision-making process and to select the most appropriate control and purification method for the specific sample and the experimental goal. The framework is implemented in the following steps: 1. Identify the sample type and the expected inhibitor class. 2. Select the control level based on the sample type. 3. Run the control and the dilution series. 4. Interpret the results and identify the inhibitor class. 5. Select the purification method based on the inhibitor class. 6. Validate the purification by running the control after purification. 7. Record the results and the inhibition index. The framework is a practical tool for the laboratory. It is not a substitute for the judgment of the researcher. The researcher should use the framework to make informed decisions and to ensure the validity of the RT-PCR results. ### The Limitations of the Decision Framework The decision framework is a practical tool, but it has limitations. The framework is based on the assumption that the inhibitor class can be identified from the sample type and the control results. This assumption is not always valid. The sample may contain multiple inhibitors, and the inhibitor class may not be identifiable from the dilution pattern. The framework is also based on the assumption that the purification method is effective for the inhibitor class. This assumption is not always valid. The purification method may not remove all inhibitors, and the purification method may introduce new inhibitors. The framework is a starting point for the researcher. The researcher should use the framework to guide the decision and to adapt the framework to the specific sample and the experimental goal. The researcher should also consult the [NIST laboratory programs](https://www.nist.gov/laboratories) for the measurement science and the standards that are used to validate the assay. ### The Framework and the MIQE Guidelines The decision framework is consistent with the [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762). The guidelines recommend that the sample processing, the controls, and the performance of the assay be reported. The framework provides a structured method for selecting the controls and for reporting the results. The framework also emphasizes the importance of the inhibition index and the dilution series. These are the quantitative measures that are recommended by the MIQE guidelines. The framework provides a practical method for implementing the MIQE recommendations in the laboratory. ### The Framework and the Biosafety Context The decision framework is a practical tool for the laboratory, but it is not a substitute for the biosafety principles. The [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) provides the principles of biosafety, including the risk assessment, the containment, and the institutional oversight. The risk assessment should be performed before the work begins, and the appropriate containment should be used. The framework is also consistent with the [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules). The guidelines provide the official oversight for the research involving the recombinant or synthetic nucleic acids. The framework is used in this research, and the guidelines should be followed. ### The Framework and the Laboratory Records The decision framework is a practical tool for the laboratory. It is designed to be used with the records and the measurements that are described in the Records and Measurements section. The framework provides the structure for the records and the measurements, and the records and the measurements provide the data for the framework. The framework is a practical tool for the laboratory. It is not a substitute for the judgment of the researcher. The researcher should use the framework to guide the decision and to adapt the framework to the actual sample and the experimental goal. The researcher should also use the [NIST laboratory programs](https://www.nist.gov/laboratories) for the measurement science and the standards that are used to validate the assay. ### The Framework and the Common Failure Patterns The framework is a practical tool for the laboratory. It is designed to address the common failure patterns that are described in the Common Failure Patterns section. The framework provides a structured method for the detection and the management of the inhibition. The framework is a practical tool for the laboratory. It is not a substitute for the judgment of the researcher. The researcher should use the framework to guide the decision and to adapt the framework to the actual sample and the experimental goal. The researcher should also use the [NIST laboratory programs](https://www.nist.gov/laboratories) for the measurement science and the standards that are used to validate the assay. ### The Framework and the Professional Escalation The framework is a practical tool for the laboratory. It is not a substitute for the professional escalation. The escalation should be considered when the inhibition cannot be resolved by the methods described in this article. The escalation may involve the following: - The use of a different extraction method - The use of a different purification method - The use of a different RT-PCR kit - The use of a different detection method The escalation should be performed in consultation with a laboratory supervisor or a specialist. The [NIST laboratory programs](https://www.nist.gov/laboratories) provide the standards and the measurement science that can be used to the escalation. ### The Framework and the Educational Context The framework is a practical tool for the laboratory. It is designed to be used in the educational context. The framework provides a structured method for the teaching of the RT-PCR inhibition. The framework is a practical tool for the laboratory. It is not a substitute for the judgment of the researcher. The researcher should use the framework to guide the informed decisions and to adapt the framework to the actual sample and the researcher. The researcher should also use the [Addgene protocols](https://www.addgene.org/protocols) for the educational molecular-biology workflow context and the practical planning. ## Frequently Asked Questions ### What is the most common cause of RT-PCR inhibition? The most common cause of RT-PCR inhibition is the presence of contaminants in the RNA sample. These contaminants can be salts, organic solvents, or biological molecules that interfere with the reverse transcriptase or the DNA polymerase. The specific contaminant depends on the sample type and the extraction method. ### How can I detect RT-PCR inhibition? The most reliable method to detect RT-PCR inhibition is to use a spike-in control. A known amount of RNA is added to the sample, and the amplification of the spike-in is measured. If the spike-in is not amplified, the sample is inhibitory. The spike-in control should be included in every RT-PCR run. ### Can I dilute my sample to reduce inhibition? Dilution can reduce the concentration of inhibitors, but it also reduces the concentration of the target RNA. The dilution should be tested in a series to determine the optimal dilution that reduces the inhibition without losing the target signal. The dilution is not a substitute for purification. ### What is the best purification method for RT-PCR? The best purification method depends on the sample type and the inhibitor. Column-based purification is a common method that removes many inhibitors. The purification method should be validated by testing the spike-in control after purification. ### What is the role of the MIQE guidelines in RT-PCR? The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) provide a framework for the reporting of qPCR and RT-PCR experiments. The guidelines recommend that the sample processing, the controls, and the performance of the assay be reported. The guidelines are intended to improve the reproducibility of the experiments. ### What is the difference between RT-PCR and qPCR? RT-PCR is a method that converts RNA to cDNA and then amplifies the cDNA. qPCR is a method that measures the amplification of the DNA in real time. RT-PCR can be combined with qPCR to measure the amount of RNA in a sample. The combination is called RT-qPCR. ### What is the role of the NIST in RT-PCR? The [NIST laboratory programs](https://www.nist.gov/laboratories) provide the measurement science and standards that are used in RT-PCR. The standards are used to calibrate the instruments and to ensure the accuracy of the measurements. The NIST also provides the reference materials that are used to validate the assay. ### What is the biosafety level for RT-PCR? The biosafety level for RT-PCR depends on the sample type and the risk assessment. The [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) provides the guidelines for the biosafety levels. The risk assessment should be performed before the sample is handled. --- ## Related Molecular Biology Guides - [Environmental Contamination PCR: Sources, Prevention, and Control](/knowledge/molecular-biology/environmental-contamination-pcr) - [Taq Polymerase: The Enzyme That Powers PCR](/knowledge/molecular-biology/taq-polymerase-an-enzyme) - [Transcription Opportunities: A Beginner's Guide to RNA Synthesis](/knowledge/molecular-biology/transcription-opportunities) - [Transcription PDF: A Comprehensive Guide to RNA Synthesis](/knowledge/molecular-biology/transcription-pdf) - [Transcription Termination: How RNA Synthesis Ends](/knowledge/molecular-biology/transcription-termination) ## References and Further Reading - [Molecular Biology and Laboratory Methods](https://www.ncbi.nlm.nih.gov/books). National Library of Medicine. - [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH. - [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules). National Institutes of Health. - [Addgene Protocols](https://www.addgene.org/protocols). Addgene. - [MIQE Guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762). Clinical Chemistry. - [NIST Laboratory Programs](https://www.nist.gov/laboratories). National Institute of Standards and Technology. - [Alleviating Cell Lysate-Induced Inhibition to Enable RT-PCR from Single Cells in Picoliter-Volume Double Emulsion Droplets.](https://pubmed.ncbi.nlm.nih.gov/36598332). Analytical chemistry, 2023. - [Have you tried spermine? A rapid and cost-effective method to eliminate dextran sodium sulfate inhibition of PCR and RT-PCR.](https://pubmed.ncbi.nlm.nih.gov/29107603). Journal of microbiological methods, 2018. - [Inhibition of real-time RT-PCR quantification due to tissue-specific contaminants.](https://pubmed.ncbi.nlm.nih.gov/15036369). Molecular and cellular probes, 2004. - [Detection and quantification of human and bovine noroviruses by a TaqMan RT-PCR assay with a control for inhibition.](https://pubmed.ncbi.nlm.nih.gov/18424068). Molecular and cellular probes, 2008. - [A SYBR Green RT-PCR assay in single tube to detect human and bovine noroviruses and control for inhibition.](https://pubmed.ncbi.nlm.nih.gov/18702817). Virology journal, 2008. > This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.